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lterations in the Pattern of Collagen Deposition
ay Contribute to the Deterioration of Systolic
unction in Hypertensive Patients With Heart Failure
egoña López, PHD,* Arantxa González, PHD,* Ramón Querejeta, MD, PHD,† Mariano Larman, MD,‡
avier Díez, MD, PHD*§
amplona and San Sebastián, Spain
OBJECTIVES We sought to assess the distribution of collagen deposits and collagen degradation in
hypertensive patients with either systolic heart failure (SHF) or diastolic heart failure (DHF).
BACKGROUND Increased collagen synthesis and deposition have been described in the myocardium of heart
failure (HF) hypertensive patients.
METHODS We studied 39 HF hypertensive patients subdivided into two groups: 16 with SHF and 23
with DHF. Endomyocardial biopsies were performed to quantify mysial (i.e., perimysial plus
endomysial) and perivascular and scar-related collagen volume fraction (CVF). Matrix
metalloproteinase (MMP)-1 and its tissue inhibitor matrix metalloproteinase (TIMP)-1 were
analyzed in cardiac samples by Western blot and immunohistochemistry, and in blood
samples by enzyme-linked immunosorbent assay.
RESULTS Mysial CVF was lower in SHF hypertensive patients than in normotensive (p  0.05) and
DHF hypertensive patients (p  0.01). Perivascular and scar-related CVF was higher (p 
0.05) in the two groups of hypertensive patients than in normotensive subjects, and in SHF
hypertensive compared with DHF hypertensive patients. The MMP-1:TIMP-1 ratio was
increased (p 0.05) in tissue and serum samples from the SHF hypertensive group compared
with the other two groups of subjects. The MMP-1 expression was increased (p  0.01) in
the interstitium and cardiomyocytes of SHF hypertensive patients compared with DHF
hypertensive and normotensive subjects. The serum MMP-1:TIMP-1 ratio was inversely
correlated with ejection fraction (r  0.510, p  0.001) and directly correlated with left
ventricular end-diastolic diameter (r  0.549, p  0.001) in all subjects.
CONCLUSIONS These findings show that the pattern of collagen deposits and the balance of the MMP-1/
TIMP-1 system are different in the myocardium of SHF and DHF hypertensive patients. It
is proposed that excessive degradation of mysial collagen may be related to the compromise
of systolic function in HF hypertensive patients. (J Am Coll Cardiol 2006;48:89–96)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.01.077© 2006 by the American College of Cardiology Foundation
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dypertension is the major risk factor for heart failure (HF)
1). Myocardial fibrosis has been proposed as a major
eterminant of altered left ventricular (LV) filling leading to
iastolic dysfunction and failure in hypertensive people (2).
owever, in a recent study we did not find differences in the
See page 97
otal fraction of myocardial volume occupied by fibrillar
ollagen (collagen volume fraction [CVF]) between patients
ith either diastolic heart failure (DHF) or systolic heart
ailure (SHF) of hypertensive etiology (3). In addition, we
From the *Division of Cardiovascular Sciences, Centre for Applied Medical
esearch, School of Medicine, University of Navarra, Pamplona, Spain; †Division of
ardiology, Donostia University Hospital, San Sebastián, Spain; ‡Division of
emodynamics, Guipúzcoa Polyclinics, San Sebastián, Spain; and the §Department
f Cardiology and Cardiovascular Surgery, University Clinic, University of Navarra,
amplona, Spain. This work was supported by a grant from the UTE Project
IMA and by grant RECAVA C03/01 from the Fondo de Investigaciones
anitarias, Ministry of Health, Spain. Drs. López and González contributed
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Manuscript received November 10, 2005; revised manuscript received December
3, 2005, accepted January 16, 2006.ound that collagen type I synthesis was inversely correlated
ith ejection fraction (EF) in these hypertensive patients
3). Up to now, data about mechanisms involved in extra-
ellular collagen degradation (i.e., the enzyme system of
atrix metalloproteinases [MMPs]) and distribution of
ollagen deposits (i.e., mysial or related to muscle compart-
ents and perivascular and scar-related) in HF hypertensive
atients have been unavailable.
Findings from a number of experimental (4–6) and
linical (7–9) studies suggest an initial inhibition of MMP
ctivity during pressure overload hypertrophy. However,
ver time, it has been shown in spontaneously hypertensive
ats (SHRs) that MMP levels and activity increase within
he myocardium and this is associated with development of
V dilation and failure (7,8,10). Interestingly, it has been
eported that MMP inhibition attenuates LV enlargement
nd dysfunction in SHRs with HF (11).
We thus have hypothesized that enhanced MMP-
ediated collagen degradation may be a contributor of LV
ilation and the deterioration of EF in HF hypertensive
atients. To test this hypothesis, we studied the myocardial
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Collagen Degradation and Heart Failure July 4, 2006:89–96xpression of MMP-1 and its tissue inhibitor matrix metal-
oproteinase (TIMP)-1 and the amount and distribution of
brillar collagen deposits in hypertensive subjects with
ither SHF or DHF. In addition, the serum levels of
MP-1 and TIMP-1 were analyzed in the same patients to
xplore the potential usefulness of the MMP-1:TIMP-1
atio as a marker of myocardial collagen degradation in these
atients.
ETHODS
ubjects. All subjects gave written informed consent to
articipate in the study, and the institutional review com-
ittee approved the study protocol. The study conformed to
he principles of the Helsinki Declaration.
The hypertensive population consisted of 39 white
atients with repeated measurements of systolic blood
ressure and diastolic blood pressure of 139 and/or 89
m Hg, respectively, consecutively enrolled from January
003 to December 2004. All patients underwent appropri-
te clinical and laboratory evaluation to exclude secondary
ypertension. All patients exhibited hypertensive heart dis-
ase as indicated by the presence of left ventricular hyper-
rophy (LVH) in the echocardiogram (see the text that
ollows). Other cardiac diseases associated with LVH and
oronary artery disease were excluded after complete med-
cal examination, which included a diagnostic cardiac cath-
terization. All patients had a previous clinical diagnosis of
hronic HF based on the presence of at least one major and
wo minor Framingham criteria (12). After echocardio-
raphic evaluation (see text that follows), the patients were
lassified into two groups: 16 exhibiting an EF 0.40
SHF) and 23 presenting an EF0.40 (DHF). None of the
atients presented any conditions associated with alterations
n serum levels of MMP-1 or TIMP-1 (rheumatoid arthri-
Abbreviations and Acronyms
ADU  arbitrary densitometric unit
CVF  collagen volume fraction
DHF  diastolic heart failure
EF  ejection fraction
ELISA  enzyme-linked immunosorbent assay
HF  heart failure
LV  left ventricle/ventricular
LVEDD  left ventricular end-diastolic diameter
LVESWS  left ventricular end-systolic
circumferential wall stress
LVH  left ventricular hypertrophy
LVMI  left ventricular mass index
MMP  matrix metalloproteinase
NT-proBNP  amino-terminal pro-brain natriuretic
peptide
SHF  systolic heart failure
SHR  spontaneously hypertensive rat
TIMP  tissue inhibitor matrix metalloproteinaseis, cancer, pulmonary fibrosis, and liver cirrhosis). dTwenty healthy, normotensive subjects (16 men and 4
omen; mean age, 51 years; range, 33 to 72 years) were used
s control subjects for biochemical parameters. A group of
0 normal hearts (from 6 men and 4 women; mean age, 59
ears; range, 40 to 68 years) collected from a total of 100
utopsies at the University Clinic of Navarra during 1998
nd 1999 served as controls for myocardial studies after
ardiac disease had been excluded. An additional group of
ve explanted hearts from patients with HF and LV dilation
ubmitted to cardiac transplantation were examined to
ssess whether interventricular septum is representative of
he LV free wall in terms of collagen deposition.
ssessment of LV dimensions, mass, and function. Two-
imensional echocardiographic imaging, targeted M-mode
ecordings, and Doppler ultrasound measurements were
btained in each patient as previously described (13). The
resence of LVH was established when left ventricular mass
ndex (LVMI) was 111 g/m2 for men and 106 g/m2 in
omen (14). The presence of LV dilation was established
hen left ventricular end-diastolic diameter (LVEDD) was
56 mm (15). Left ventricular end-systolic circumferential
all stress (LVESWS) was calculated in accordance with
ouglas et al. (16).
istomorphological and immunohistochemical studies.
hree transvenous endomyocardial biopsies were taken
rom the middle area of the interventricular septum with a
ioptome (96 cm [7-F]; Cordis Corp., Miami Lakes,
lorida), under fluoroscopic guidance after angiographic
xamination, and CVF was determined with an automated
mage analysis system in sections stained with collagen-
pecific picrosirius red, as previously reported (13). Two
atterns of collagen deposition were defined according to its
ocalization: mysial (collagen associated with groups of cells or
erimysium, and collagen which surrounds and interconnects
ndividual cells or endomysium), and perivascular and scar-
elated collagen (Fig. 1). Thus, total and perivascular and
car-related CVF were measured, and mysial CVF was calcu-
ated as the subtraction of perivascular and scar-related CVF
rom total CVF.
Immunohistochemical analysis for MMP- and TIMP-1
as performed on formalin-fixed and paraffin-embedded
ections. Immunohistochemical staining was performed by
he avidin peroxidase-labeled dextran polymer method.
ositive staining was visualized with DAB plus (Boehringer
annheim Corp., Indianapolis, Indiana) and tissues were
ounterstained with Harris hematoxylin (Sigma, St. Louis,
issouri). A mouse monoclonal antibody against MMP-1
dilution 1:200; Oncogene, San Diego, California) and
IMP-1 (dilution 1:100; Chemicon, Temecula, California)
as used as the primary antibody. A semiquantitative scale
as developed to measure the expression of interstitial and
ardiomyocyte MMP- and TIMP-1 seen at high power
40). The amount of these molecules was graded on a
cale of 0 to 3, with 0 representing the absence of deposits,
 being mild deposits, 2 corresponding to moderate
eposits, and 3 being intense deposits.
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July 4, 2006:89–96 Collagen Degradation and Heart FailureThe histomorphological study was performed by two
athologists blinded to the other characteristics of the
atients studied.
estern blot studies. To analyze the expression of MMP-
nd TIMP-1 proteins, aliquots containing 10 g of total
rotein were diluted in 4 sample buffer (40%
-mercaptoethanol, 8% SDS, 40% glycerol, 0.025% bromo-
henol blue, and 0.25 mmol/l Tris, pH 6.4), separated by
lectrophoresis on 10% polyacrylamide gel, and transferred
nto nitrocellulose membranes. Specific monoclonal anti-
odies against MMP-1 (Oncogene) and TIMP-1 (Chemi-
on) were incubated at a dilution of 1:2,000 and 1:200,
espectively. Bands were detected by incubation with
eroxidase-conjugated anti-mouse IgG (Amersham, Buck-
nghamshire, United Kingdom) at a dilution of 1:10,000
nd 1:5,000, respectively (Fig. 2A). The blots were also
ested with a monoclonal -actin antibody (Sigma) as a
igure 1. Endomyocardial tissue from one hypertensive patient with hea
dentified in red (40). Collagen tissue was seen as thin bands surroundin
anel), as large strands localized around intramyocardial vessels (perivascul
nterstitium (scar collagen, right panel).
igure 2. (A) Representative Western blot autoradiogram of the 52-kDa
ndomyocardial samples from one normotensive patient, one hypertensive
eart failure. (B) Bars represent mean  SEM of the ratio of MMP- to TI
HF  diastolic heart failure; HT  hypertensive; MMP  matrix metalloprot
nhibitor matrix metalloproteinase.ontrol for loading (Fig. 2A). Data are expressed as arbitrary
ensitometric units (ADUs) relative to -actin expression.
iochemical determinations. Venous blood samples were
btained in each patient from the coronary sinus and the left
ntecubital vein during the cardiac catheterism procedure
n which endomyocardial biopsies were performed. Free
MP- and TIMP-1 were determined in serum by enzyme-
inked immunosorbent assay (ELISA) methods as previ-
usly reported (7). The levels of the amino-terminal pro-
rain natriuretic peptide (NT-proBNP) were measured in
erum samples by ELISA according to Karl et al. (17).
tatistical analysis. To analyze the differences between the
ormotensive group and the two groups of hypertensive
ubjects, a one-way analysis of variance followed by a
tudent-Newman-Keuls test was performed once normality
as checked (Shapiro-Wilks test); otherwise, the nonpara-
etric Kruskal-Wallis test followed by a Mann-Whitney
lure. Sections were stained with picrosirius red and collagen fibers were
ividual cardiomyocytes or groups of cardiomyocytes (mysial collagen, left
lagen, middle panel), and as masses or scars diffusely localized within the
P-1 protein and the 28-kDa TIMP-1 protein. Autoradiograms include
nt with diastolic heart failure, and one hypertensive patient with systolic
1, calculated in endomyocardial samples from the three groups of subjects.rt fai
g ind
ar colMM
patie
MP-einase; NT  normotensive; SHF  systolic heart failure; TIMP  tissue
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Collagen Degradation and Heart Failure July 4, 2006:89–96test (adjusting the -level by Bonferroni inequality) was
sed. Differences between the two groups of hypertensive
atients were tested by a Student t test for unpaired data
nce normality was demonstrated; otherwise, a nonpara-
etric test (Mann-Whitney U test) was used. Categorical
ariables were analyzed by the chi-square Fisher exact test
hen necessary. The MMP-1:TIMP-1 ratio in peripheral
ein blood and NT-proBNP were normalized by logarith-
ic transformation for the correlational analysis. The cor-
elation between continuously distributed variables was
ested by univariate regression analysis. Values are expressed
s mean  SEM. A value of p  0.05 was considered
tatistically significant.
ESULTS
linical characteristics of hypertensive patients. Baseline
linical characteristics of the two groups of hypertensive
able 1. Clinical Parameters Determined in Hypertensive
atients With Chronic Heart Failure
Parameters DHF Patients SHF Patients
ge, yrs 62  3 65  3
ender, male/female 17/6 12/4
ime of diagnosis of HF, days 663  106 967  225
ody mass index, kg/m2 27.93  0.72 28.90  0.71
YHA functional class
I – –
II 5 2
III 14 8
IV 4 6
edications
ACEIs or ARAs 23 16
Beta-blockers 21 15
Digoxin 11 8
Loop diuretics 23 16
lood pressure, mm Hg
Systolic 147  2 140  5
Diastolic 88  1 87  3
eart rate, beats/min 69.6  3.0 74.1  4.5
V posterior wall thickness, mm 9.40  0.20 9.80  0.40
V septal thickness, mm 10.62  0.40 10.93  0.65
V mass index, g/m2 133  9 181  16†
elative wall thickness, mm 0.37  0.01 0.33  0.01*
V end-diastolic diameter, mm 52  2 61  3†
V end-systolic diameter, mm 33  2 51  2‡
V end-diastolic volume, ml 134  10 193  17†
V end-systolic volume, ml 50  6 130  13‡
V end-systolic circumferential
wall stress, 103 dynes/cm2
247  11 268  20
E:VA 1.17  0.09 1.49  0.35
eceleration time, ms 213  11 175  14*
sovolumic relaxation time, ms 101  3 111  5
jection fraction, % 0.60  0.02 0.30  0.01‡
ICP, g/l 130  7 142  8*
T-proBNP, pg/ml 830  156 1,196  283*
alues are expressed as number of subjects, and as mean  SEM. *p  0.05; †p 
.01; ‡p  0.001, compared with DHF patients.
ACEI  angiotensin-converting enzyme inhibitor; ARA  angiotensin receptor
ntagonist; DHF  diastolic heart failure; HF  heart failure; IV  interventricular;
V  left ventricular; NT-proBNP  amino-terminal pro-brain natriuretic peptide;
YHA  New York Heart Association; PICP  carboxyterminal propeptide ofs
rocollagen type I; SHF  systolic heart failure; VA  maximum late transmitral
elocity in diastole; VE  maximum early transmitral velocity in diastole.atients are presented in Table 1. Although the duration of
F did tend to be higher in SHF than in DHF hyperten-
ive patients, the difference did not reach statistical signif-
cance. No differences were observed between the two
roups of patients in the distribution of the different classes
f pharmacological compounds. Values of LVMI and rela-
ive wall thickness were higher and lower, respectively, in
HF hypertensive patients than in the DHF hypertensive
roup. As expected, SHF hypertensive subjects exhibited
igher values of LV chamber diameters and volumes and
ower values of EF than DHF hypertensive patients. Left
entricle dilatation was present in 75% and 35% of patients
n the SHF and the DHF groups, respectively, this differ-
nce being significant (chi square  6.109, p  0.02). The
evel of NT-proBNP was increased (p  0.001) in the two
roups of hypertensive patients compared with the normo-
ensive group (36  5 pg/ml). The values of this parameter
id tend to be higher in SHF than in DHF hypertensive
atients, but the differences did not reach statistical
ignificance.
ssessment of cardiac collagen. Total CVF measured in
he interventricular septum of failing and dilated hearts was
imilar to that measured in the free wall of the LV (7.95 
.84% vs. 7.64  0.49%). Thus, interventricular septum
amples can be considered as representative for the LV
yocardium.
As shown in Table 2, the values of total CVF were higher
p  0.01) in DHF and SHF hypertensive patients than in
he normotensive group. No differences in this parameter
ere found between the two groups of patients. Mysial
VF was decreased in the SHF hypertensive group com-
ared with normotensive (p  0.05) and DHF hypertensive
atients (p  0.01). No differences in this parameter were
ound between normotensive and DHF hypertensive
atients. Perivascular and scar-related CVF was higher (p
.05) in the two groups of hypertensive patients than in the
ormotensive group. In addition, perivascular and scar-
elated CVF was increased (p  0.05) in SHF hypertensive
atients compared with DHF hypertensive subjects.
ssessment of cardiac MMP-1 and TIMP-1. Figure 2A
hows a representative Western blot autoradiogram of
MP- and TIMP-1 proteins in myocardial tissue. The
xpression of MMP-1 was higher (p  0.05) in the SHF
ypertensive group (1.40  0.20 ADU) than in normoten-
able 2. Collagen Volume Fraction in Normotensive Subjects
nd Hypertensive Patients With Chronic Heart Failure
Collagen Volume
Fraction (%)
Normotensive
Patients DHF Patients SHF Patients
otal 1.9  0.7 7.3  0.6† 8.1  0.9†
ysial 1.8  0.1 2.6  0.5 1.3  0.1*§
erivascular and
scar-related
0.1  0.02 4.7  0.6* 6.8  0.8*‡
alues are expressed as mean  SEM. *p  0.05; †p  0.01, compared with
ormotensive patients. ‡p  0.05; §p  0.01, compared with DHF patients.
Abbreviations as in Table 1.ive (0.96  0.16 ADU) and DHF hypertensive patients
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July 4, 2006:89–96 Collagen Degradation and Heart Failure0.97  0.06 ADU). No differences in the expression of
IMP-1 were observed among the three groups of subjects
normotensive 1.05 0.20 ADU; DHF 0.95 0.04 ADU;
HF 1.15  0.12 ADU). As a consequence, the ratio of
MP- to TIMP-1 was significantly enhanced in SHF
atients compared with the other two groups of subjects
Fig. 2B).
Although no cardiomyocyte expression of MMP- and
IMP-1 was observed in normotensive subjects, these two
roteins were expressed in cardiomyocytes from HF hyper-
ensive patients (Fig. 3). Whereas more patients exhibited
ow grades of cardiomyocyte MMP-1 expression in the DHF
roup, more patients exhibited high grades in the SHF group
Table 3). No differences in cardiomyocyte TIMP-1 expres-
ion were observed between the two groups of patients.
Interstitial expression of MMP- and TIMP-1 was de-
ected in the three groups of subjects (data not shown). More
atients exhibited high grades of interstitial MMP-1 expres-
ion in the SHF group than in the DHF group (Table 3). In
ontrast, more patients exhibited high grades of interstitial
IMP-1 expression in the DHF group than in the SHF
roup (Table 3).
ssessment of serum free MMP- and free TIMP-1. The
alues of MMP-1 (15.94  0.86 ng/ml) and TIMP-1
1,387  79 ng/ml) in coronary sinus blood were higher
p  0.001) than MMP-1 (12.85  0.83 ng/ml) and
IMP-1 (1,194  52 ng/ml) in peripheral vein blood in
ypertensive patients, but not in normotensive subjects
coronary sinus blood: MMP-1 4.91  0.55 ng/ml,
igure 3. Endomyocardial tissue from one normotensive patient (A and
ypertensive patient with systolic heart failure (C and F). Sections were
nti-TIMP-1 (D, E, and F), and these molecules were identified in brow
100.) Abbreviations as in Figure 2.IMP-1 290  47 ng/ml; peripheral vein blood: MMP-1 T.82  0.35 ng/ml, TIMP-1 588  22 ng/ml). In addition,
irect correlations were found between MMP-1 in coronary
inus blood and peripheral vein blood (r  0.641, p 
.001) and TIMP-1 in coronary sinus blood and peripheral
ein blood (r  0.625, p  0.001) in all hypertensive
atients.
The level of MMP-1 in peripheral vein blood was
ncreased (p  0.001) in SHF (15.10  1.72 ng/ml) and
HF (11.70 1.00 ng/ml) hypertensive patients compared
ith the normotensive group (4.82  0.35 ng/ml). In
ne hypertensive patient with diastolic heart failure (B and E), and one
nostained with an antibody anti-MMP-1 (A, B, and C) or an antibody
hin the cardiomyocytes. Arrows highlight specific points. (Magnification:
able 3. Grade of MMP-1 and TIMP-1 Deposits in
ormotensive Subjects and Hypertensive Patients With
hronic Heart Failure
Grade
Normotensive
Patients
DHF
Patients
SHF
Patients
CM INT CM INT CM INT
MP-1 0 100 0 0 0 0 0
1 0 80 60 20 20 10
2 0 20 40 40 40 30
3 0 0 0 40 40 60
* ‡ *† ‡§
IMP-1 0 100 0 20 0 30 0
1 0 80 40 20 40 40
2 0 20 20 40 10 40
3 0 0 0 40 0 20
* ‡ * ‡§
alues represent the percentage of patients in each group. *p  0.01 compared with
M in normotensive patients; †p  0.01 compared with CM in DHF patients; ‡p 
.05 compared with INT in normotensive patients; §p 0.01 compared with INT in
HF patients.D), o
immuCM  cardiomyocytes; INT  interstitium; MMP-1  matrix metalloproteinase 1;
IMP-1  tissue inhibitor of MMP-1; other abbreviations as in Table 1.
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Collagen Degradation and Heart Failure July 4, 2006:89–96ddition, MMP-1 in peripheral vein blood was higher (p 
.05) in SHF patients than in DHF patients. The level of
IMP-1 in peripheral vein blood was higher (p  0.001) in
he two groups of hypertensive patients (SHF 1,076  78
g/ml; DHF 1,275  73 ng/ml) than in the normotensive
roup (588 22 ng/ml). In addition, TIMP-1 in peripheral
ein blood was decreased (p  0.05) in SHF patients
ompared with DHF patients. Thus, the ratio of MMP- to
IMP-1 in peripheral vein blood was increased in SHF
ypertensive patients (1.51  0.22) compared with both
ormotensive (0.83  0.06, p  0.01) and DHF hyperten-
ive subjects (0.99  0.11, p  0.05). No differences in this
igure 4. (A) Direct correlation (y  0.03  4.75) between left ventricula
lood in all subjects. (B) Direct correlation (y  5.28  1.93) between log
ein blood in all subjects. LV  left ventricular; NT-proBNP  amino-term
igure 5. (A) Inverse correlation (y  33.39  49.97) between the ratio
nd ejection fraction in all subjects. (B) Direct correlation (y  1.98  5.50) betw
nd-diastolic diameter in all subjects. EF  ejection fraction; LVEDD  left ventarameter were observed between these two groups of
ubjects.
nalysis of associations. Direct correlations were found
etween LVESWS and MMP-1 in peripheral vein blood
r  0.301, p  0.05) (Fig. 4A) and between NT-proBNP
nd MMP-1 in peripheral vein blood (r  0.593, p 
.001) (Fig. 4B) in all subjects. The ratio of MMP-1 to
IMP-1 in peripheral vein blood was inversely correlated
ith EF (r  0.510, p  0.001) (Fig. 5A) and directly
orrelated with LVEDD (r  0.549, p  0.001) (Fig. 5B)
n all subjects. Interestingly, significant associations were
ound between the ratio of MMP-1 to TIMP-1 in periph-
systolic circumferential wall stress and MMP-1 measured in peripheral vein
-terminal pro-brain natriuretic peptide and MMP-1 measured in peripheral
ro-brain natriuretic peptide; other abbreviations as in Figure 2.
P-1 to TIMP-1 (log MMP-1:TIMP-1) measured in peripheral vein bloodr end-of MM
een log MMP-1:TIMP-1 measured in peripheral blood and left ventricular
ricular end-diastolic diameter; other abbreviations as in Figure 2.
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July 4, 2006:89–96 Collagen Degradation and Heart Failureral vein blood 1.12 and EF 0.40 (chi square  5.96, p
0.02), and LVEDD 56 mm (chi square  6.01, p 
.02).
ISCUSSION
he main findings of this study are as follows: 1) whereas
ysial collagen deposits are diminished, perivascular and
car-related collagen deposits are increased in SHF hyper-
ensive compared with DHF hypertensive patients; 2) an
xcess of MMP-1 relative to TIMP-1 is present in the
yocardium of SHF hypertensive compared with DHF
ypertensive patients; 3) up-regulated expression of
MP-1 is detected at both the cardiomyocyte and the
nterstitial level in SHF hypertensive patients; and
) increased serum MMP-1:TIMP-1 ratio is associated
ith LV dilatation and systolic dysfunction in HF hyper-
ensive patients.
athophysiological meaning. Besides their rate of synthe-
is and activation, the actual activity of MMPs depends
ritically on the balance between active enzyme and TIMPs.
hus, our finding of increased cardiac MMP-1:TIMP-1
atio in SHF hypertensive subjects suggests that MMP-1
ctivity is enhanced in these patients. Interestingly, the
ardiac MMP-1:TIMP-1 ratio was normal in DHF hyper-
ensive subjects, suggesting that disregulation of the cardiac
MP-1/TIMP-1 system is a characteristic feature of hyper-
ensive patients with SHF. This possibility is in agreement
ith previous studies showing that in the hearts of patients
ith aortic stenosis, a pre-dominant expression of MMP-1
ver TIMP-1 is present in the hearts of patients with
epressed EF compared with patients with preserved EF
18,19).
It is likely that up-regulation of MMP-1 in SHF hyper-
ensive patients is a dynamic process and is determined by
he co-occurrence of a number of intracellular and extracel-
ular signals. For instance, a number of humoral factors (i.e.,
nflammatory mediators, neurohormones, and bioactive
eptides) may contribute to MMP-1 up-regulation in SHF
ypertensive patients (20). In addition, mechanical signals
inked to LV wall stress may result in the induction of
yocardial MMP-1 (21). In support of these mechanisms,
e found that serum levels of MMP-1 were associated with
T-proBNP and LVESWS.
A clear cause-and-effect relationship between excessive
yocardial MMP activity, collagen degradation, and pro-
ression to SHF has been shown experimentally through
he use of transgenic models and the use of pharmacologic
MP inhibitors. For instance, it has been demonstrated
hat acute MMP activation and disruption of the fibrillar
ollagen network in the pressure overload hypertrophied
yocardium causes a decrease in systolic performance with-
ut changing cardiomyocyte contractility (22). In addition,
t has been reported that transgenic mice with cardiac-
estricted overexpression of human MMP-1 exhibit loss of
ollagen network accompanied by a marked deterioration of dystolic function (23). In this context, our finding that the
eduction of mysial collagen is associated with an intense
xpression of MMP-1 in cardiomyocytes from SHF
atients may be of interest. In fact, experimental evidence
as been provided showing that following chronic neuro-
ormonal activation, increased synthesis and release of
MPs into the local extracellular matrix of the cardiomy-
cyte occurs (24), which in turn could contribute to en-
omysial and perimysial collagen degradation and disrup-
ion. The loss of the mysial collagen network may
ompromise systolic function through three possible mech-
nisms (25,26). The first implies discontinuities in the
ysial collagen matrix that provides support, geometric
lignment, and coordination of adjacent cardiomyocyte
ascicle contraction. The second involves the loss of the
ormal collagen matrix-basement membrane-integrin con-
ections that contribute to the synchrony and synergy of
arcomeres during the contractile process. The third is
elated to sliding displacements (slippage) of cardiomyo-
ytes leading to a decrease in the number of muscular layers
n the ventricular wall and LV dilation, which in turn
mpairs the working conditions of the LV myocardium.
linical application. Some findings reported here may be
f clinical interest. The higher concentrations of MMP-
nd TIMP-1 in coronary sinus blood versus peripheral vein
lood, found in hypertensive but not in normotensive
atients, and the correlations between their peripheral and
oronary sinus levels suggest that circulating MMP- and
IMP-1 detected in HF hypertensive patients may be of
ardiac origin and that the peripheral MMP-1:TIMP-1
atio may be useful as an index of the MMP-1/TIMP-1
alance within the myocardium. The clinical relevance of
he MMP-1:TIMP-1 ratio determined in peripheral vein
lood is further supported by its associations with parame-
ers assessing LV systolic dysfunction (depressed EF) and
emodeling (increased LVEDD). Therefore, because the
etermination of MMP- and TIMP-1 in serum is simple,
eproducible, and low-cost, it might be useful for noninva-
ive screening for the MMP-1/TIMP-1 system in selected
F hypertensive patients, adding further diagnostic and
rognostic information for the assessment of these patients.
tudy limitations. This was a study involving a relatively
mall number of patients, but because of the nature of the
oals under investigation, this design is appropriate. In
ddition, it must be recognized that therapy with different
ypes of drugs may have confounded the findings and their
nterpretation. Nevertheless, since they are standard thera-
ies for hypertension and HF, it is unreasonable to with-
raw them for purposes of this investigation. In addition, no
ifferences in the distribution of the different types of drugs
ere found between the two groups of patients.
Although we performed biopsies of the interventricular
eptum to assess changes in collagen in the LV, data here
resented indicate that in terms of CVF, the septum is
epresentative of the free wall. This is in agreement with
ata by Pearlman et al. (27) showing that collagen changes
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Collagen Degradation and Heart Failure July 4, 2006:89–96resent in the septum in post-mortem tissue from hyper-
ensive, hypertrophic, non-dilated human hearts are repre-
entative of changes existing in the free wall.
Although a number of MMP and TIMP species are
xpressed within the human myocardium, only MMP- and
IMP-1 were examined in the current study. In addition,
o direct assessment of tissue MMP activity (i.e., zymog-
aphy) was performed. Therefore, further studies are re-
uired to identify the complete portfolio of MMPs and
IMPs that are functionally altered in HF hypertensive
atients.
onclusions. We report that an association exists between
ardiomyocyte MMP-1 up-regulation, reduction of mysial
ollagen, and SHF in hypertensive patients. Thus, a new
aradigm is proposed in the sense that beyond perivascular
nd scar-related fibrosis secondary to excessive collagen
ynthesis, exaggerated perimysial and endomysial collagen
egradation may contribute critically to deterioration of
ystolic function in hypertensive patients.
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